Patents by Inventor Reiji Kannagi
Reiji Kannagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8580925Abstract: [PROBLEMS] To provide examination methods and reagents able to detect efficiently cancer patients and patients at high risk of cancer. [MEANS FOR SOLVING PROBLEMS] Significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, between non-carcinoma tissues and carcinoma tissues or adenoma tissues were discovered. The discovery is evidently applicable to detect carcinomas and adenomas (except colorectal carcinomas and colorectal adenomas) specifically by assaying a certain range of GlcNAc-6-sulfated sugar residue groups in tissues of patients and in fecal samples. Examination of carcinomas and adenomas is possible by the use of antibodies reacting specifically with GlcNAc-6-sulfated sugar residues specifically synthesized by enzymes present in carcinoma and adenoma tissues.Type: GrantFiled: December 15, 2005Date of Patent: November 12, 2013Assignees: Japan Science and Technology Agency, Local Government of Aichi Prefecture, Wako Pure Chemical Industries, Ltd.Inventors: Reiji Kannagi, Mineko Izawa, Naoko Kimura, Shunsuke Kurei, Kazue Watanabe
-
Publication number: 20100137564Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide having the amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which includes an amino acid sequence including substitution, deletion, insertion or transposition of one or a few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented the formula I: GlcNAc?1-3Gal?1-4GlcNAc??(I) where GlcNAc represents an N-acetyl-glucosamine residue, Gal represents a galactose residue, ? 1-3 represents a ? 1-3 glycosidic linkage, and ? 1-4 represents a ? 1-4 glycosidic linkage.Type: ApplicationFiled: August 19, 2008Publication date: June 3, 2010Applicant: Aichi PrefectureInventors: Kenji Uchimura, Hideki Muramatsu, Kenji Kadomatsu, Reiji Kannagi, Osami Habuchi, Takashi Muramatsu
-
Publication number: 20100015632Abstract: The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. There are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore, colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No.Type: ApplicationFiled: September 28, 2009Publication date: January 21, 2010Applicant: Japan Science and Technology AgencyInventors: Reiji Kannagi, Mineko Izawa, Takashi Muramatsu, Kenji Uchimura, Hideaki Hosokawa
-
Patent number: 7601348Abstract: The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No.Type: GrantFiled: July 9, 2004Date of Patent: October 13, 2009Assignees: Japan Science & Technology Agency, Local Government of Aichi Prefecture, Wako Pure Chemical Industries, Ltd.Inventors: Reiji Kannagi, Mineko Izawa, Takashi Muramatsu, Kenji Uchimura, Hideaki Hosokawa
-
Patent number: 7423126Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I: GlcNAc?1-3Gal?1-4GlcNAc ??(I) wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, ?1-3 represents a ?1-3 glycosidic linkage, and ?1-4 represents a ?1-4 glycosidic linkage.Type: GrantFiled: October 15, 2004Date of Patent: September 9, 2008Assignee: Aichi PrefectureInventor: Reiji Kannagi
-
Publication number: 20080096234Abstract: [PROBLEMS] To provide examination methods and reagents able to detect efficiently cancer patients and patients at high risk of cancer. [MEANS FOR SOLVING PROBLEMS] Significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, between non-carcinoma tissues and carcinoma tissues or adenoma tissues were discovered. The discovery is evidently applicable to detect carcinomas and adenomas (except colorectal carcinomas and colorectal adenomas) specifically by assaying a certain range of GlcNAc-6-sulfated sugar residue groups in tissues of patients and in fecal samples. Examination of carcinomas and adenomas is possible by the use of antibodies reacting specifically with GlcNAc-6-sulfated sugar residues specifically synthesized by enzymes present in carcinoma and adenoma tissues.Type: ApplicationFiled: December 15, 2005Publication date: April 24, 2008Inventors: Reiji Kannagi, Mineko Izawa, Naoko Kimura, Shunsuke Kurei, Kazue Watanabe
-
Publication number: 20070196874Abstract: The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. The present inventors discovered that there are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore the inventors applied the discovery to diagnosis and found that colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No.Type: ApplicationFiled: July 9, 2004Publication date: August 23, 2007Inventors: Reiji Kannagi, Mineko Izawa, Takashi Muramatsu, Kenji Uchimura, Hideaki Hosokawa
-
Publication number: 20050208631Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I: GlcNAc?1-3Gal ?1-4GlcNAc??(I) wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, ?1-3 represents a ?1-3 glycosidic linkage, and ?1-4 represents a ?1-4 glycosidic linkage.Type: ApplicationFiled: October 15, 2004Publication date: September 22, 2005Inventors: Kenji Uchimura, Hideki Muramatsu, Kenji Kadomatsu, Reiji Kannagi, Osami Habuchi, Takashi Muramatsu
-
Publication number: 20050142644Abstract: Apolypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I: GlcNAc?1-3Gal?1-4GlcNAc ??(I) wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, ?1-3 represents a ?1-3 glycosidic linkage, and ?1-4 represents a ?1-4 glycosidic linkage.Type: ApplicationFiled: October 15, 2004Publication date: June 30, 2005Inventors: Kenji Uchimura, Hideki Muramatsu, Kenji Kadomatsu, Reiji Kannagi, Osami Habuchi, Takashi Muramatsu
-
Publication number: 20030008366Abstract: Apolypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided.Type: ApplicationFiled: August 5, 2002Publication date: January 9, 2003Inventors: Kenji Uchimura, Hideki Muramatsu, Kenji Kadomatsu, Reiji Kannagi, Osami Habuchi, Takashi Muramatsu
-
Patent number: 6455289Abstract: Apolypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I: GlcNAc&bgr;1-3Gal&bgr;1-4GlcNAc (I) wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, &bgr;1-3 represents a &bgr;1-3 glycosidic linkage, and &bgr;1-4 represents a &bgr;1-4 glycosidic linkage.Type: GrantFiled: December 23, 1999Date of Patent: September 24, 2002Assignee: Seikagaku CorporationInventors: Kenji Uchimura, Hideki Muramatsu, Kenji Kadomatsu, Reiji Kannagi, Osami Habuchi, Takashi Muramatsu
-
Patent number: 6037159Abstract: Apolypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below:(a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or(b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I:GlcNAc.beta.1-3Gal.beta.1-4GlcNAc (I)wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, .beta.1-3 represents a .beta.1-3 glycosidic linkage, and .beta.1-4 represents a .beta.1-4 glycosidic linkage.Type: GrantFiled: March 5, 1999Date of Patent: March 14, 2000Assignee: Seikagaku CorporationInventors: Kenji Uchimura, Hideki Muramatsu, Kenji Kadomatsu, Reiji Kannagi, Osami Habuchi, Takashi Muramatsu
-
Patent number: 5173420Abstract: A monoclonal antibody A exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.9NeuAc terminal. A monoclonal antibody B exhibits specificity to the sialic acid glycolipid containing the epitope NeuAc.alpha.2.fwdarw.6Gal.beta. terminal. A monoclonal antibody C exhibits specificity to the sialic acid glycolipid containing at least one epitope selected from the group of NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer. Hybridomas are prepared which produce antibodies A, B and C. A process for producing the hybridomas is disclosed including the step of fusing a myeloma cell and a B cell (lymphocyte) produced by the immunization of animal using as an antigen, the sialic acid glycolipid containing at least one epitope of the group NeuAc.alpha.2.fwdarw.9NeuAc terminal, NeuAc.alpha.2.fwdarw.6Gal.beta. terminal and NeuAc.alpha.2.fwdarw.1Cer.Type: GrantFiled: February 15, 1989Date of Patent: December 22, 1992Assignee: MECT CorporationInventors: Reiji Kannagi, Yoshiko Kirihata, Tomoya Ogawa, Masaaki Numata, Mamoru Sugimoto
-
Patent number: 4885358Abstract: Hybridomas which produce monoclonal antibodies specific to an abnormal branched determinant of a synthetic glycolipid antigen and methods of use of the monoclonal antibodies.Type: GrantFiled: February 11, 1987Date of Patent: December 5, 1989Assignee: MECT CorporationInventors: Reiji Kannagi, Katsuyoshi Shigeta, Yukishige Ito, Yoshiko Kirihata, Tomoya Ogawa